Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Starbuck1990 - EGF binding and trafficking dynamics in Fibroblast

ABSTRACT: mathematical model, with accompanying quantitative experimental data, for binding and trafficking properties of the epidermal growth factor (EGF) receptor on B82 fibroblasts, and propose a theoretical dependence of cell proliferation rate on these properties. Model encoded by Matthieu Maire adn submitted to BioModels by Krishna Kumar Tiwari.

SUBMITTER: Krishna Kumar Tiwari

PROVIDER: MODEL2003190005 | BioModels | 2020-03-19

REPOSITORIES: BioModels

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MODEL2003190005?filename=Starbuck1990.cps	Other
	MODEL2003190005?filename=Starbuck1990.sedml	Other
	MODEL2003190005?filename=Starbuck1990.xml	Xml

Items per page:

1 - 3 of 3

Similar Datasets

Bayleyegn2016 - interactions of CycE/Cdk2, Cdc25A, and P27 Kip1 in a core cancer subnetwork

Project description:Mathematical description of the interactions of CycE/Cdk2, Cdc25A, and P27Kip1 in a core cancer subnetwork. Model is encoded by Matthieu Maire/partially by Krishna Kumar Tiwari and submitted to BioModels by Krishna Kumar Tiwari.

2020-03-18 | MODEL2003180002 | BioModels

Gidvani2012 - DNA replication initiation model in S. Cevevisiae

Project description:A quantitative model of the initiation of DNA replication in Saccharomyces cerevisiae predicts the effects of system perturbations. Model is encoded by Matthew Maire and submitted in BioModels by Krishna Kumar Tiwari.

2020-05-06 | MODEL2003180001 | BioModels

Novak1998 - Mathematical model of fission yeast cell cycle

Project description:Mathematical model of the fission yeast cell cycle with checkpoint controls at the G1/S, G2/M and metaphase/anaphase transitions. Model encoded by Matthieu Maire and submitted to BioModels by Krishna kumar Tiwari.

2020-03-19 | MODEL2003190004 | BioModels

Chiorino2002 - G1/S transition model

Project description:mathematical approach to model the protein interactions regulating the transition from the G1 phase to the phase of DNA synthesis. Model is encoded by matthieu Maire and submitted to BioModels by krishna kumar tiwari.

2020-03-19 | MODEL2003180003 | BioModels

Vibert2017 - Tcell proliferation model

Project description:model allows us to infer proliferation rates and cell cycle phase durations from complex experimental 5-ethynyl-2'-deoxyuridine (EdU) data, revealing T cell proliferation heterogeneity and specific signatures. Model is encoded by Matthew Maire and submitted in BioModels by Krishna Kumar Tiwari.

2020-03-17 | MODEL2003170002 | BioModels

Liu2017 - chemotherapy targeted model of tumor immune system

Project description:Its a mathematical model reflecting chemotherapy response in tumor immune interaction system. Model encoded by Sarubini Kananathan and annotated+submitted to Biomodels by Krishna Tiwari

2024-09-02 | BIOMD0000000930 | BioModels

MIRO2-mediated mitochondrial transfer from cancer cells induces cancer-associated fibroblast differentiation

Project description:Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment that commonly support cancer development and progression. Here we show that different cancer cells transfer mitochondria to fibroblasts in co-cultures and xenograft tumors, thereby inducing pro-tumorigenic CAF features. Transplantation of functional mitochondria from cancer cells induces metabolic alterations in fibroblasts, expression of CAF markers, and release of a pro-tumorigenic secretome and matrisome. These features promote tumor formation in pre-clinical mouse models. Mechanistically, the mitochondrial transfer requires the mitochondrial trafficking protein MIRO2. Its depletion in cancer cells suppresses mitochondrial transfer and inhibits CAF differentiation and tumor growth. The clinical relevance of these findings is reflected by the overexpression of MIRO2 in tumor cells at the leading edge of epithelial skin cancers. These results identify mitochondrial transfer from cancer cells to fibroblasts as a driver of tumorigenesis and provide a rationale for targeting MIRO2 and mitochondrial transfer in different malignancies.

2025-05-19 | GSE267826 | GEO

Wu2017 - Murine Bevacizumab PK model

Project description:This is the first report evaluating the use of fluorescent imaging to determine the pharmacokinetics, lymphatic uptake, and bioavailability of a near-infrared dye-labeled antibody conjugate. Model is encoded by Matthew Roberts and submitted to BioModels by Krishna Tiwari.

2025-01-15 | MODEL2003030003 | BioModels

Genome-wide CTCF binding maps in mouse ES and fibroblast cells

Project description:Chromatin immunoprecipitation against CTCF followed by Illumina High-throughput sequencing. Examination of CTCF binding in embryonic stem cells and embryonic fibroblasts

2011-04-15 | E-GEOD-27944 | biostudies-arrayexpress

Paradoxical drug sensitization of lung cancer cells by stromal fibroblast-secreted IGF-binding proteins: Secretomics

Project description:Cancer-associated fibroblasts (CAFs) are an integral part of the tumor microenvironment often linked to drug resistance. Here, we report that CAFs, but not normal fibroblasts, can promote either resistance or unexpected drug sensitization of different lung cancer cells. Using unbiased secretomics, transcriptomics and tyrosine phosphoproteomics, we observed differential expression of several IGF1R signaling components, such as IGF-binding proteins and IGF1/2, and downstream signaling effects on cancer cells by fibroblasts. IGF1/2 treatment or IGFBP5 silencing in CAFs reversed, while addition of exogenous IGFBPs or pharmacological IGF1R inhibitors phenocopied the sensitizing effects. Combining IGF1R and EGFR inhibitors synergized in 2D and 3D models of different drug-resistant and naïve EGFR-mutant lung cancer cells and decreased tumor growth in vivo. These results suggest that multiple resistance mechanisms coexist within the same cancer cells, that CAFs context-dependently cause drug resistance or sensitization, and that understanding both of these differential mechanisms leads to improved therapeutic approaches.

2023-03-11 | PXD023626 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data